Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000071.xml
Download PDF
Semin Neurol 2017; 37(02): 158-166
DOI: 10.1055/s-0037-1602424
DOI: 10.1055/s-0037-1602424
Review Article
Nonmotor Symptoms in Parkinson's Disease
Further Information
Publication History
Publication Date:
16 May 2017 (online)
Abstract
Nonmotor symptoms (NMSs) in Parkinson's disease (PD) have become increasingly recognized as major determinants of quality of life across cultures worldwide. Behavioral symptoms include dementia, depression, anxiety, apathy, and fatigue. Somatic symptoms include hypotension, constipation, diaphoresis, and pain. However, somatic symptoms may also be intrinsic, such as dementia, and iatrogenic, such as compulsive disorders. The authors address some of the more common disorders, yet few have been the target of clinical trials.
-
References
- 1 Weintraub D, Simuni T, Caspell-Garcia C. , et al; Parkinson's Progression Markers Initiative. Cognitive performance and neuropsychiatric symptoms in early, untreated Parkinson's disease. Mov Disord 2015; 30 (07) 919-927
- 2 Emre M, Aarsland D, Brown R. , et al. Clinical diagnostic criteria for dementia associated with Parkinson's disease. Mov Disord 2007; 22 (12) 1689-1707 , quiz 1837
- 3 Aarsland D, Andersen K, Larsen JP. , et al. The rate of cognitive decline in Parkinson disease. Arch Neurol 2004; 61 (12) 1906-1911
- 4 Kalbe E, Rehberg SP, Heber I. , et al. Subtypes of mild cognitive impairment in patients with Parkinson's disease: evidence from the LANDSCAPE study. J Neurol Neurosurg Psychiatry 2016; 87 (10) 1099-1105
- 5 de Lau LM, Verbaan D, Marinus J, van Hilten JJ. Survival in Parkinson's disease. Relation with motor and non-motor features. Parkinsonism Relat Disord 2014; 20 (06) 613-616
- 6 Forsaa EB, Larsen JP, Wentzel-Larsen T, Alves G. What predicts mortality in Parkinson disease?: a prospective population-based long-term study. Neurology 2010; 75 (14) 1270-1276
- 7 Pigott K, Rick J, Xie SX. , et al. Longitudinal study of normal cognition in Parkinson disease. Neurology 2015; 85 (15) 1276-1282
- 8 Cereda E, Cilia R, Klersy C. , et al. Dementia in Parkinson's disease: Is male gender a risk factor?. Parkinsonism Relat Disord 2016; 26: 67-72
- 9 Anang JB, Gagnon J-F, Bertrand J-A. , et al. Predictors of dementia in Parkinson disease: a prospective cohort study. Neurology 2014; 83 (14) 1253-1260
- 10 Kempster PA, O'Sullivan SS, Holton JL, Revesz T, Lees AJ. Relationships between age and late progression of Parkinson's disease: a clinico-pathological study. Brain 2010; 133 (Pt 6): 1755-1762
- 11 Monchi O, Hanganu A, Bellec P. Markers of cognitive decline in PD: The case for heterogeneity. Parkinsonism Relat Disord 2016; 24: 8-14
- 12 Williams-Gray CH, Evans JR, Goris A. , et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009; 132 (Pt 11): 2958-2969
- 13 Mata IF, Leverenz JB, Weintraub D. , et al. GBA Variants are associated with a distinct pattern of cognitive deficits in Parkinson's disease. Mov Disord 2016; 31 (01) 95-102
- 14 Oeda T, Umemura A, Mori Y. , et al. Impact of glucocerebrosidase mutations on motor and nonmotor complications in Parkinson's disease. Neurobiol Aging 2015; 36 (12) 3306-3313
- 15 Fuchs J, Nilsson C, Kachergus J. , et al. Phenotypic variation in a large Swedish pedigree due to SNCA duplication and triplication. Neurology 2007; 68 (12) 916-922
- 16 Chen B, Fan GG, Liu H, Wang S. Changes in anatomical and functional connectivity of Parkinson's disease patients according to cognitive status. Eur J Radiol 2015; 84 (07) 1318-1324
- 17 Hanganu A, Bedetti C, Degroot C. , et al. Mild cognitive impairment is linked with faster rate of cortical thinning in patients with Parkinson's disease longitudinally. Brain 2014; 137 (Pt 4): 1120-1129
- 18 Hanağası HA, Bilgiç B, Emre M. Dementia with Lewy bodies and Parkinson's disease dementia. In: Husain M, Schott JM. , eds. Oxford Textbook of Cognitive Neurology and Dementia. Oxford, England: Oxford University Press; 2016: 399-412
- 19 Szeto JY, Mowszowski L, Gilat M, Walton CC, Naismith SL, Lewis SJ. Assessing the utility of the Movement Disorder Society Task Force Level 1 diagnostic criteria for mild cognitive impairment in Parkinson's disease. Parkinsonism Relat Disord 2015; 21 (01) 31-35
- 20 Goldman JG, Holden S, Ouyang B, Bernard B, Goetz CG, Stebbins GT. Diagnosing PD-MCI by MDS Task Force criteria: how many and which neuropsychological tests?. Mov Disord 2015; 30 (03) 402-406
- 21 Marras C, Tröster AI, Kulisevsky J, Stebbins GT. The tools of the trade: a state of the art “How to Assess Cognition” in the patient with Parkinson's disease. Mov Disord 2014; 29 (05) 584-596
- 22 Gustafsson H, Nordström A, Nordström P. Depression and subsequent risk of Parkinson disease: A nationwide cohort study. Neurology 2015; 84 (24) 2422-2429
- 23 Bulloch AG, Fiest KM, Williams JV. , et al. Depression--a common disorder across a broad spectrum of neurological conditions: a cross-sectional nationally representative survey. Gen Hosp Psychiatry 2015; 37 (06) 507-512
- 24 Inoue T, Kitagawa M, Tanaka T, Nakagawa S, Koyama T. Depression and major depressive disorder in patients with Parkinson's disease. Mov Disord 2010; 25 (01) 44-49
- 25 Riedel O, Bitters D, Amann U, Garbe E, Langner I. Estimating the prevalence of Parkinson's disease (PD) and proportions of patients with associated dementia and depression among the older adults based on secondary claims data. Int J Geriatr Psychiatry 2016; 31 (08) 938-943
- 26 Hsu Y-T, Liao C-C, Chang S-N. , et al. Increased risk of depression in patients with Parkinson disease: a nationwide cohort study. Am J Geriatr Psychiatry 2015; 23 (09) 934-940
- 27 Wee N, Kandiah N, Acharyya S. , et al. Depression and anxiety are co-morbid but dissociable in mild Parkinson's disease: A prospective longitudinal study of patterns and predictors. Parkinsonism Relat Disord 2016; 23: 50-56
- 28 Kadastik-Eerme L, Rosenthal M, Paju T, Muldmaa M, Taba P. Health-related quality of life in Parkinson's disease: a cross-sectional study focusing on non-motor symptoms. Health Qual Life Outcomes 2015; 13 (01) 83
- 29 Santos-García D, de la Fuente-Fernández R. Factors contributing to caregivers' stress and burden in Parkinson's disease. Acta Neurol Scand 2015; 131 (04) 203-210
- 30 Hu X, Song X, Yuan Y. , et al. Abnormal functional connectivity of the amygdala is associated with depression in Parkinson's disease. Mov Disord 2015; 30 (02) 238-244
- 31 Wen MC, Chan LL, Tan LC, Tan EK. Depression, anxiety, and apathy in Parkinson's disease: insights from neuroimaging studies. Eur J Neurol 2016; 23 (06) 1001-1019
- 32 Castrén E. Neuronal network plasticity and recovery from depression. JAMA Psychiatry 2013; 70 (09) 983-989
- 33 D'Ostilio K, Garraux G. The network model of depression as a basis for new therapeutic strategies for treating major depressive disorder in Parkinson's disease. Front Hum Neurosci 2016; 10: 161
- 34 Bomasang-Layno E, Fadlon I, Murray AN, Himelhoch S. Antidepressive treatments for Parkinson's disease: A systematic review and meta-analysis. Parkinsonism Relat Disord 2015; 21 (08) 833-842 , discussion 833
- 35 Adamson BC, Ensari I, Motl RW. Effect of exercise on depressive symptoms in adults with neurologic disorders: a systematic review and meta-analysis. Arch Phys Med Rehabil 2015; 96 (07) 1329-1338
- 36 Xie C-L, Chen J, Wang X-D. , et al. Repetitive transcranial magnetic stimulation (rTMS) for the treatment of depression in Parkinson disease: a meta-analysis of randomized controlled clinical trials. Neurol Sci 2015; 36 (10) 1751-1761
- 37 Shin H-W, Youn YC, Chung SJ, Sohn YH. Effect of high-frequency repetitive transcranial magnetic stimulation on major depressive disorder in patients with Parkinson's disease. J Neurol 2016; 263 (07) 1442-1448
- 38 Borisovskaya A, Bryson WC, Buchholz J, Samii A, Borson S. Electroconvulsive therapy for depression in Parkinson's disease: systematic review of evidence and recommendations. Neurodegener Dis Manag 2016; 6 (02) 161-176
- 39 Dissanayaka NN, Sellbach A, Matheson S. , et al. Anxiety disorders in Parkinson's disease: prevalence and risk factors. Mov Disord 2010; 25 (07) 838-845
- 40 Pontone GM, Williams JR, Anderson KE. , et al. Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease. Mov Disord 2009; 24 (09) 1333-1338
- 41 Richard IH. Anxiety disorders in Parkinson's disease. Adv Neurol 2005; 96: 42-55
- 42 Siemers ER, Shekhar A, Quaid K, Dickson H. Anxiety and motor performance in Parkinson's disease. Mov Disord 1993; 8 (04) 501-506
- 43 Stein MB, Heuser IJ, Juncos JL, Uhde TW. Anxiety disorders in patients with Parkinson's disease. Am J Psychiatry 1990; 147 (02) 217-220
- 44 Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Symptomatology and markers of anxiety disorders in Parkinson's disease: a cross-sectional study. Mov Disord 2011; 26 (03) 484-492
- 45 Henderson R, Kurlan R, Kersun JM, Como P. Preliminary examination of the comorbidity of anxiety and depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 1992; 4 (03) 257-264
- 46 Leentjens AF, Dujardin K, Marsh L, Martinez-Martin P, Richard IH, Starkstein SE. Anxiety and motor fluctuations in Parkinson's disease: a cross-sectional observational study. Parkinsonism Relat Disord 2012; 18 (10) 1084-1088
- 47 Menza MA, Sage J, Marshall E, Cody R, Duvoisin R. Mood changes and “on-off” phenomena in Parkinson's disease. Mov Disord 1990; 5 (02) 148-151
- 48 Prediger RD, Matheus FC, Schwarzbold ML, Lima MM, Vital MA. Anxiety in Parkinson's disease: a critical review of experimental and clinical studies. Neuropharmacology 2012; 62 (01) 115-124
- 49 Yang S, Sajatovic M, Walter BL. Psychosocial interventions for depression and anxiety in Parkinson's disease. J Geriatr Psychiatry Neurol 2012; 25 (02) 113-121
- 50 Marino L, Friedman JH. Letter to the editor: successful use of electroconvulsive therapy for refractory anxiety in Parkinson's disease. Intl J Neurosci 2012; 123 (01) 70-71
- 51 Pagonabarraga J, Kulisevsky J, Strafella AP, Krack P. Apathy in Parkinson's disease: clinical features, neural substrates, diagnosis, and treatment. Lancet Neurol 2015; 14 (05) 518-531
- 52 den Brok MG, van Dalen JW, van Gool WA, Moll van Charante EP, de Bie RM, Richard E. Apathy in Parkinson's disease: a systematic review and meta-analysis. Mov Disord 2015; 30 (06) 759-769
- 53 Maillet A, Krack P, Lhommée E. , et al. The prominent role of serotonergic degeneration in apathy, anxiety and depression in de novo Parkinson's disease. Brain 2016; 139 (Pt 9): 2486-2502
- 54 Lees AJ, Blackburn NA, Campbell VL. The nighttime problems of Parkinson's disease. Clin Neuropharmacol 1988; 11 (06) 512-519
- 55 Oerlemans WG, de Weerd AW. The prevalence of sleep disorders in patients with Parkinson's disease. A self-reported, community-based survey. Sleep Med 2002; 3 (02) 147-149
- 56 Arnulf I, Konofal E, Merino-Andreu M. , et al. Parkinson's disease and sleepiness: an integral part of PD. Neurology 2002; 58 (07) 1019-1024
- 57 Maria B, Sophia S, Michalis M. , et al. Sleep breathing disorders in patients with idiopathic Parkinson's disease. Respir Med 2003; 97 (10) 1151-1157
- 58 Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996; 46 (02) 388-393
- 59 Boeve BF, Silber MH, Parisi JE. , et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 2003; 61 (01) 40-45
- 60 Iranzo A, Santamaría J, Rye DB. , et al. Characteristics of idiopathic REM sleep behavior disorder and that associated with MSA and PD. Neurology 2005; 65 (02) 247-252
- 61 Boeve BF, Silber MH, Ferman TJ. Melatonin for treatment of REM sleep behavior disorder in neurologic disorders: results in 14 patients. Sleep Med 2003; 4 (04) 281-284
- 62 Weintraub D, David AS, Evans AH, Grant JE, Stacy M. Clinical spectrum of impulse control disorders in Parkinson's disease. Mov Disord 2015; 30 (02) 121-127
- 63 Kim J, Kim M, Kwon DY. , et al. Clinical characteristics of impulse control and repetitive behavior disorders in Parkinson's disease. J Neurol 2013; 260 (02) 429-437
- 64 Fernandez HH, Friedman JH. Punding on L-dopa. Mov Disord 1999; 14 (05) 836-838
- 65 Seedat S, Kesler S, Niehaus DJ, Stein DJ. Pathological gambling behaviour: emergence secondary to treatment of Parkinson's disease with dopaminergic agents. Depress Anxiety 2000; 11 (04) 185-186
- 66 Rylander G. Psychoses and the punding and choreiform syndromes in addiction to central stimulant drugs. Psychiatr Neurol Neurochir 1972; 75 (03) 203-212
- 67 Friedman JH, Agarwal P, Alcalay R. , et al. Clinical vignettes in Parkinson's disease: a collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. Int J Neurosci 2011; 121 (08) 472-476
- 68 Weintraub D, Koester J, Potenza MN. , et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 2010; 67 (05) 589-595
- 69 Lee J-Y, Kim J-M, Kim JW. , et al. Association between the dose of dopaminergic medication and the behavioral disturbances in Parkinson disease. Parkinsonism Relat Disord 2010; 16 (03) 202-207
- 70 Poletti M, Logi C, Lucetti C. , et al. A single-center, cross-sectional prevalence study of impulse control disorders in Parkinson disease: association with dopaminergic drugs. J Clin Psychopharmacol 2013; 33 (05) 691-694
- 71 Joutsa J, Martikainen K, Vahlberg T, Voon V, Kaasinen V. Impulse control disorders and depression in Finnish patients with Parkinson's disease. Parkinsonism Relat Disord 2012; 18 (02) 155-160
- 72 Antonini A, Siri C, Santangelo G. , et al. Impulsivity and compulsivity in drug-naïve patients with Parkinson's disease. Mov Disord 2011; 26 (03) 464-468
- 73 Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005; 65 (10) 1570-1574
- 74 Moore TJ, Glenmullen J, Mattison DR. Reports of pathological gambling, hypersexuality, and compulsive shopping associated with dopamine receptor agonist drugs. JAMA Intern Med 2014; 174 (12) 1930-1933
- 75 Cornelius JR, Tippmann-Peikert M, Slocumb NL, Frerichs CF, Silber MH. Impulse control disorders with the use of dopaminergic agents in restless legs syndrome: a case-control study. Sleep 2010; 33 (01) 81-87
- 76 Bancos I, Nannenga MR, Bostwick JM, Silber MH, Erickson D, Nippoldt TB. Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf) 2014; 80 (06) 863-868
- 77 Zhang S, Dissanayaka NN, Dawson A. , et al. Management of impulse control disorders in Parkinson's disease. Int Psychogeriatr 2016; 28 (10) 1-8
- 78 Nirenberg MJ. Dopamine agonist withdrawal syndrome: implications for patient care. Drugs Aging 2013; 30 (08) 587-592
- 79 Friedman JH, Brown RG, Comella C. , et al; Working Group on Fatigue in Parkinson's Disease. Fatigue in Parkinson's disease: a review. Mov Disord 2007; 22 (03) 297-308
- 80 Friedman J, Friedman H. Fatigue in Parkinson's disease. Neurology 1993; 43 (10) 2016-2018
- 81 Schifitto G, Friedman JH, Oakes D. , et al; Parkinson Study Group ELLDOPA Investigators. Fatigue in levodopa-naive subjects with Parkinson disease. Neurology 2008; 71 (07) 481-485
- 82 Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinson's disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010; 133 (11) 3434-3443
- 83 Shulman LM, Taback RL, Rabinstein AA, Weiner WJ. Non-recognition of depression and other non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord 2002; 8 (03) 193-197
- 84 Mendonça DA, Menezes K, Jog MS. Methylphenidate improves fatigue scores in Parkinson disease: a randomized controlled trial. Mov Disord 2007; 22 (14) 2070-2076
- 85 Giuffrida R, Vingerhoets FJ, Bogousslavsky J, Ghika J. [Pain in Parkinson's disease]. Rev Neurol (Paris) 2005; 161 (04) 407-418
- 86 Schrag A, Jahanshahi M, Quinn N. How does Parkinson's disease affect quality of life? A comparison with quality of life in the general population. Mov Disord 2000; 15 (06) 1112-1118
- 87 Goetz CG, Tanner CM, Levy M, Wilson RS, Garron DC. Pain in Parkinson's disease. Mov Disord 1986; 1 (01) 45-49
- 88 Chudler EH, Dong WK. The role of the basal ganglia in nociception and pain. Pain 1995; 60 (01) 3-38
- 89 Menza MA, Golbe LI, Cody RA, Forman NE. Dopamine-related personality traits in Parkinson's disease. Neurology 1993; 43 (3 Pt 1): 505-508
- 90 Arabia G, Grossardt BR, Colligan RC. , et al. Novelty seeking and introversion do not predict the long-term risk of Parkinson disease. Neurology 2010; 75 (04) 349-357
- 91 Bower JH, Grossardt BR, Maraganore DM. , et al. Anxious personality predicts an increased risk of Parkinson's disease. Mov Disord 2010; 25 (13) 2105-2113
- 92 Tanner C, Albers K, Goldman S. , et al. Seborrheic dermatitis and risk of future Parkinson's disease (PD) (S42. 001). Neurology 2012; 78 (1, Suppl S42.001): 42
- 93 Gregory R, Miller S. Parkinson's disease and the skin. Pract Neurol 2015; 15 (04) 246-249
- 94 Huang P, Yang X-D, Chen S-D, Xiao Q. The association between Parkinson's disease and melanoma: a systematic review and meta-analysis. Transl Neurodegener 2015; 4 (01) 21
- 95 Bourghli A, Guérin P, Vital J-M. , et al. Posterior spinal fusion from T2 to the sacrum for the management of major deformities in patients with Parkinson disease: a retrospective review with analysis of complications. J Spinal Disord Tech 2012; 25 (03) E53-E60
- 96 Moon S-H, Lee H-M, Chun H-J. , et al. Surgical outcome of lumbar fusion surgery in patients with Parkinson disease. J Spinal Disord Tech 2012; 25 (07) 351-355
- 97 Sarkiss CA, Fogg GA, Skovrlj B, Cho SK, Caridi JM. To operate or not?: A literature review of surgical outcomes in 95 patients with Parkinson's disease undergoing spine surgery. Clin Neurol Neurosurg 2015; 134: 122-125
- 98 Friedman JH, Dighe G. Systematic review of caudal epidural injections in the management of chronic back pain. R I Med J (2013) 2013; 96 (01) 12-16